The effects of bosentan, aminoguanidine and L-canavanine on mesenteric blood flow, spleen and liver in endotoxaemic mice

European Journal of Pharmacology

Volumn 379, Issue 1, 1999, Pages 73-80

  Iskit, Alper B ^a   Sungur, Arzu ^a   Gedikoglu, Gokhan ^a   Oguz Guc, M ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Aminoguanidine; Bosentan; Endothelin; L canavanine; Nitric oxide NO; Sepsis

Indexed keywords

AMINOGUANIDINE; BOSENTAN; CANAVANINE; ESCHERICHIA COLI ENDOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; ENDOTOXEMIA; LIVER BLOOD FLOW; LIVER WEIGHT; MESENTERY BLOOD FLOW; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SPLEEN BLOOD FLOW; SPLEEN WEIGHT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BODY WEIGHT; CANAVANINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTOXINS; GUANIDINES; LIVER; MICE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; ORGAN SIZE; RECEPTORS, ENDOTHELIN; SPLANCHNIC CIRCULATION; SPLEEN; SULFONAMIDES;

EID: 0032693278     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00432-X     Document Type: Article

References (43)

1. Bieganski T., Kusche J., Lorenz W., Hesterberg R., Stahlknecht C.D., Feussner K.D. Distribution and properties of human diamine oxidase and its relevance for the histamine catabolism. Biochem. Biophys. Acta. 756:1983;196-203.
2. Bone R.C. Sepsis, the sepsis syndrome, multiple organ failure: a plea for comparable definitions. Ann. Intern. Med. 114:1990;332-333.
3. Butler A.R., Flintney F.W., Williams L.H. NO, nitrosonium ions, nitroxide ions, iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol. Sci. 16:1995;18-22.
4. Clozel M., Breu V., Gray G.A., Kalina B., Loffer B.-M., Burri K., Cassal J.M., Hirth G., Muller M., Neidhart W., Ramuz H. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270:1994;228-235.
5. Gardiner S.M., Kemp P.A., March J.E., Bennett T. Enhancement of the hypotensive and vasodilator effects of endotoxaemia in conscious rats by the endothelin antagonist, SB 209670. Br. J. Pharmacol. 116:1995;1718-1719.
6. Garvey E.P., Oplinger J.A., Furfine E.S., Kiff R.J., Laszlo F., Whittle S.J.R., Knowles R.G. 1400W is a slow-, tight-binding and highly selective inhibitor of inducible nitric oxide synthase in vitro and in vivo. J. Biol. Chem. 272:1997;4959-4963.
7. Ghosh S., Latimer R.D., Gray B.M., Harwood R.J., Oduro A. Endotoxin-induced organ injury. Crit. Care Med. 21:1993;S19-S24.
8. Guc M.O., Furman B.L., Parratt J.R. Endotoxin-induced impairment of vasopressor and vasodepressor responses in the pithed rat. Br. J. Pharmacol. 101:1990;913-919.
9. Hutcheson I.R., Whittle B.J.R., Boughton-Smith N.K. Role of nitric oxide in maintaining vascular integrity in endotoxin-induced acute intestinal damage in the rat. Br. J. Pharmacol. 101:1990;815-820.
10. Iyengar R., Stuehr D.J., Marletta M.A. Macrophage synthesis of nitrite, nitrate and N-nitrosamines: precursors and role of respiratory burst. Proc. Natl. Acad. Sci. U.S.A. 84:1987;6369-6373.
11. Julou Schaeffer G., Gray G.A., Fleming I., Schott C., Parratt J.R., Stoclet J.-C. Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am. J. Physiol. 259:1990;H1039-1043.
12. Kavuklu B., Agalar C., Guc M.O., Sayek I. Evidence that aminoguanidine inhibits endotoxin-induced bacterial translocation. Br. J. Surg. 85:1998;1103-1106.
13. Kilbourn R. The discovery of nitric oxide as a key mediator in septic shock. Sepsis. 1:1998;85-91.
14. Laszlo F., Whittle B.J.R., Moncada S. Time dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors. Br. J. Pharmacol. 111:1994;1309-1315.
15. Lefer A.M. Nitric oxide donors in endotoxic and septic shock: evidence against nitric oxide as a mediator of shock. Sepsis. 1:1998;101-106.
16. Liaudet L., Feihl F., Rosselet A., Markert M., Hurni J.M., Perret C. Beneficial effects of L-canavanine, a selective inhibitor of inducible nitric oxide synthase, during rodent endotoxaemia. Clin. Sci. Colch. 90:1996;369-377.
17. Lipton S.A., Choi Y.-B., Pan Z.-H., Lei S.Z., Chen H.-S., Sucher N.J., Loscalzo J., Singel D.J., Stamler J.S. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso compounds. Nature. 364:1993;626-632.
18. MacLean, L.D., 1972. Shock: causes and management of circulatory collapse. In: Sabiston, D.C. (Ed.), Davis Christopher Textbook of Surgey. Saunders, Philadelphia, pp. 65-91.
19. MacMicking J.D., Nathan C., Hom G., Chartrain N., Fletcher D.S., Trumbauer M., Stevens K., Xie Q.W., Sokol K., Hutchinson N. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell. 82:1995;641-650.
20. Misko T.P., Moore W.M., Kasten T.P., Nickols G.A., Corbett J.A., Tilton R.G., McDaniel M.L., Williamson J.R., Currie M.G. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur. J. Pharmacol. 233:1993;119-125.
21. Mitolo-Chieppa D., Serio M., Potenza M.A., Montagnani M., Mansi G., Pece S., Jirillo E., Stoclet J.-C. Hyporeactivity of mesenteric vascular bed in endotoxin-treated rats. Eur. J. Pharmacol. 309:1996;175-182.
22. Moncada S., Higgs E.A. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 9:1995;1319-1330.
23. Ou P., Wolff S.P. A drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem. Pharmacol. 46:1993;1139-1144.
24. Parratt J.R. Nitric oxide. A key mediator in sepsis and endotoxaemia? J. Physiol. Pharmacol. 48:1997;493-506.
25. Parrillo J.E. The cardiovascular pathology of sepsis. Annu. Rev. Med. 40:1989;469-485.
26. Picard S., Parthasarthy S., Fruebis J., Witzum J.L. Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptors. Proc. Natl. Acad. Sci. U.S.A. 89:1992;6876-6880.
27. Pittet J.F., Morel D.R., Hemsen A., Gunning K., Lacroix J.S., Suter P.M., Lundberg J.M. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann. Surg. 213:1991;261-264.
28. B receptors on the liver dysfunction and injury caused by endotoxaemia in the rat. Br. J. Pharmacol. 119:1996;479-486.
29. 2+ independent nitric oxide synthase in the myocardium. Br. J. Pharmacol. 105:1992;575-580.
30. Seiler N., Bolkenius F.N., Knodgen B. The influence of catabolic reaction on polyamine excretion. Biochem. J. 225:1985;219-226.
31. Sugiura M., Inagami T., Kon V. Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassay. Biochem. Biophys. Res. Commun. 161:1989;1220-1227.
32. Takala J. Determinants of splanchnic blood flow. Br. J. Anaesth. 77:1996;50-58.
33. Thiemermann C. Nitric oxide and septic shock. Gen. Pharmacol. 29:1997;159-166.
34. Thiemermann C. The use of selective inhibitors of inducible nitric oxide in septic shock. Sepsis. 1:1998;123-129.
35. Thiemermann C., Vane J.R. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharide in the rat. Eur. J. Pharmacol. 182:1990;591-595.
36. Thiemermann C., Ruetten H., Wu C.C., Vane J.R. The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br. J. Pharmacol. 116:1995;2845-2851.
37. Vemulapalli S., Chiu P.J.S., Rivelli M., Foster C.J., Sybertz E.J. Modulation of circulating endothelin levels in hypertension and endotoxemia in rats. J. Cardiovasc. Pharmacol. 18:1991;895-903.
38. Wang P., Ba Z.F., Chaudry I.H. Hepatocellular dysfunction occurs earlier than the onset of hyperdynamic circulation during sepsis. Shock. 3:1995;21-26.
39. Weitzberg E., Lundberg J.M., Rudehill A. Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ. Shock. 33:1991;222-227.
40. Weitzberg E., Hemsen A., Rudehill A., Modin A., Wanecek M., Lundberg J.M. Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1. Br. J. Pharmacol. 118:1996;617-626.
41. Wu C.C., Chen S.J., Szabo C., Thiemermann C., Vane J.R. Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br. J. Pharmacol. 114:1995;1666-1672.
42. G-nitro-L-arginine methyl ester on the multiple organ dysfunction caused by endotoxaemia in the rat. Eur. J. Pharmacol. 300:1996;99-104.
43. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.